Compare Cognizant Technology Solutions Corp (CTSH) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Tilray Brands Inc — how do they compare? Cognizant Technology Solutions Corp trades at $59.2 (market cap $27.03B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Cognizant Technology Solutions Corp is far larger — about 50.9× Tilray Brands Inc's market cap, and Cognizant Technology Solutions Corp pays a 2.2% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Tilray Brands Inc for 31 Days on average.
| CTSH | TLRY | |
|---|---|---|
Market Cap | $27.03B | $530.54M |
Volume | 9,883,888 | 9,099,075 |
Sector | Technology | Health |
52-Week High | $86.70 | $17.20 |
52-Week Low | $38.73 | $3.54 |
Typical Hold Time | 57 Days | 31 Days |
Enterprise Value | $28.08B | $684.46M |
Dividend Yield | 2.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $60.01, up 5.15% over 24 hours, reflecting strong momentum near its pivot point of $58. The stock shows bullish technical signals with moving averages supporting an uptrend. Fundamentally, CTSH maintains solid profitability with a 10.26% net margin and a modest P/E of 12.88. Recent earnings beats in Q4 2025 and Q1 2026 were offset by a Q2 2026 miss, with Q3 2026 results pending. Positive news includes AI-driven partnerships and employer awards, enhancing its growth narrative.
CTSH presents a balanced investment case with a consensus price target of $64.25 offering ~7% upside. Strengths include stable cash flow and undervaluation relative to peers, but risks involve IT spending pressures from AI disruption and competitive threats. Analyst sentiment is evenly split between Buy and Hold, indicating cautious optimism. The stock's outlook hinges on execution in AI services and sustaining margin discipline amid industry headwinds.
TLRY trades at $3.59, down 3.36% on the day and near 52-week lows, with a bearish technical signal. The company reported revenue of $821.31M for 2025 but posted a net loss of -$2.19B, missing earnings expectations for four consecutive quarters. While analyst consensus shows 70% hold ratings, the stock faces significant profitability challenges with negative margins and cash flow concerns despite some revenue growth projections.
The outlook remains challenging with persistent losses and negative cash flow, though the stock trades at discounted valuation multiples. Key risks include ongoing profitability struggles and cannabis regulatory uncertainty. Potential catalysts include upcoming Q1 2027 earnings on October 8, 2026, and potential marijuana reform developments that could benefit the company's positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
